查詢結果分析
相關文獻
- Microangiopathic Hemolytic Anemia in a Patient with Recurrent Anal Cancer and Liver Metastasis
- 固定深度治療對直腸肛門癌放射治療的影響
- Concurrent Chemotherapy and Radiotherapy of Anal Cancer
- 肛門癌器官保留治療方式
- 肛門癌之放射線及化學合併療法
- Primary Anal Cancer
- Multimodality Treatment for Anal Cancer--A Case Report and Literature Review
- Treatment Outcomes for Epidermoid Carcinoma of the Anal Canal in a Single Institution
- 肛門癌
- Anal Canal Carcinoma Treatment Results: 10-year Experience in a Single Institution
頁籤選單縮合
題 名 | Microangiopathic Hemolytic Anemia in a Patient with Recurrent Anal Cancer and Liver Metastasis=微小血管病變及溶血性貧血於肛門癌復發合併肝轉移的病人 |
---|---|
作 者 | 葉光揚; 鄧波; 張文震; 廖宗琦; | 書刊名 | 長庚醫學 |
卷 期 | 25:10 2002.10[民91.10] |
頁 次 | 頁706-710 |
分類號 | 415.6 |
關鍵詞 | 微小血管病變溶血性貧血; 肛門癌; MAHA; Anal cancer; Mitomycin C; |
語 文 | 英文(English) |
中文摘要 | 微小血管病變溶血性貧血可以是末期癌症病患致命的併發症(癌症相關),或者發生在病人托受化學治療且腫瘤完全消失後(化學治療誘發)。以往研究指出分泌黏液性的腺癌易有微小血管病變溶血性貧血現象出?;至於鱗狀上皮癌與微小血管病變溶血性貧血之間的關係,鮮有報導。此篇報告提出一位60歲女性病人,罹患肛門鱗狀上皮癌合併肝轉移。病人在接受化學治療(mitomycin C,5-fluoruracil及 cisplatin)後,其腫瘤幾乎完全消失。然而在完成化學治療2個月後,病人發生微小血管病變溶血性貧血。五個月報,腫瘤復發且迅速變大。病人於診斷微小血管病變溶血性貧血後的第5個月死亡。這篇個案報告並非容易報區分癌症相關和化學治療誘發的微小血管病變溶血性貧血。但就臨床證據而?,作者們較支持這位肛門鱗狀上皮癌合併肝轉移病人,可能發生化學療誘發的微小血管病變溶血性貧血,但是並不排除癌症相關的微小血管病變溶血性貧血。同時,微小血管病變溶血性貧血可能是腫瘤復發的早期徵兆。 |
英文摘要 | Microangiopathic hemolytic anemia (MAHA) is a late but fetal complication in advanced caners (cancer-associated). It may also appear in complete remission after chemotherapy (chemotherapy-related). Mucin-producing adenocarcinoma has been extensively studied in relation to this phenomenon. Squamous cell carcinoma with MAHA, on the other hand, has not often been reported in the English literature. Because of the difficulty of case collection, understanding of the association of MAHA and anal squamous cell carcinoma remains vague. We present a 60-year-old woman with anal cancer and liver metastasis. This patient received chemotherapy (mitomycin C, 5-fluoruracil, and cisplatin) and reached a good partial response. MAHA developed 2 months later, and tumor recurrence with rapid deterioration appeared 5 months later. The patient died 5 months after MAH was diagnosed. We consider that the MAHA in this patient is chemotherapy-related. However, the possibility of cancer-associated MAHA could not be excluded. |
本系統中英文摘要資訊取自各篇刊載內容。